Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

NCT04323631 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT04323631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04323631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
Lead sponsor
Rambam Health Care Campus
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2020
Completion date
April 30, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19